Latest News

When it comes to realising these benefits, the trap for industry, clinicians and patients is to advocate for change in the context of Australia's existing and outdated approach to health technology assessment.

Professor David Thomas says using comprehensive molecular screening to match patients to treatment poses particular challenges for payer systems like Australia's PBS.

Josh Jordan of Roche's Foundation Medicine said the "real challenge" is ensuring patient access to the range and combination of available technologies, including genomic profiling and treatments.

New Zealand's chief coroner has opened an inquiry into the reported deaths of four people related to the forced switch of an anti-epilepsy medicine.

“The thing that makes Mundipharma such a special company is our people and our culture. I have often commented to friends and colleagues that I have the best job in the industry, and I believe that,” said the retiring managing director.

The association says it is 'astonished' after the federal government disregarded the findings of a Senate inquiry, failed to consult, and used the last day of the parliamentary sitting year to table enabling legislation that will cut the value of the R&D Tax Incentive.

"Patients will now have greater choice as to where they can receive treatment, at home or via a healthcare professional," said the company.

AstraZeneca's LYNPARZA (olaparib) will be funded for ovarian cancer in New Zealand - three years after the company submitted an application to PHARMAC.

An alliance of 22 Australian consumer groups has come together to call on governments to implement a range of reforms including an independent review of Australia’s Health Technology Assessment system.

Another confirmed speaker for the BioPharmaDispatch 2020 conference with the Australian general manager of one of the world's emerging Artifical Intelligence companies.

CSL invested over A$1.2 billion in R&D in financial year 2019 as the company progressed what it described as a "highly differentiated product portfolio mix".

As "transparent as possible" presumably means stakeholders should gain a proper understanding of how decisions are made. Surely this extends to understanding how discussants review and present submissions, what they are recommending, and the extent to which the PBAC accepts their advice.